====Neurocrine Biosciences (NBIX) reported earnings on Wed 1 Nov 2017 (a/h)

Neurocrine Biosci beats by $0.40, beats on revs 

• Reports Q3 (Sep) loss of $0.13 per share, $0.40 better than the Capital IQ Consensus of ($0.53).
• INGREZZA (valbenazine) Net Product Sales of $45.8 Million for Initial Full Quarter of Commercialization as the First U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia
• Elagolix New Drug Application for Endometriosis Granted Priority Review by FDA, PDUFA action date in Second Quarter of 2018
• Initiated INGREZZA T-Force GOLD Phase IIb Study to Assess Children and Adolescents with Tourette Syndrome
• Received $15 Million from Mitsubishi Tanabe for Initiating Pivotal Studies of INGREZZA in Asia